193 results
DEFA14A
AKBA
Akebia Therapeutics Inc.
25 Apr 24
Additional proxy soliciting materials
5:18pm
LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. For NOTE: The proxies are authorized
8-K
EX-99.1
AKBA
Akebia Therapeutics Inc.
27 Mar 24
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
8:35pm
of Medicine, Division of Nephrology at Stanford University and Co-Chair of the independent Executive Steering Committee for PRO2TECT and INNO2VATE, the global
S-8
EX-23.1
3ywjhiq8r13fz0pr
30 Jan 24
Registration of securities for employees
4:33pm
8-K
slgpfgjb xa
8 Jan 24
Departure of Directors or Certain Officers
4:08pm
8-K
yqb9fhyboptb2ia
8 Jun 23
Departure of Directors or Certain Officers
4:30pm
S-8
EX-23.1
9x0c5
6 Jun 23
Registration of securities for employees
4:18pm
S-8
EX-99.1
rm3ciwaj tphzj
6 Jun 23
Registration of securities for employees
4:18pm